Last reviewed · How we verify
Adriamycin, cyclophosphamide, vindesine, valproic acid
Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression.
Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression. Used for Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer, Multiple myeloma.
At a glance
| Generic name | Adriamycin, cyclophosphamide, vindesine, valproic acid |
|---|---|
| Sponsor | European Lung Cancer Working Party |
| Drug class | anthracycline antibiotic, alkylating agent, vinca alkaloid, histone deacetylase inhibitor |
| Target | DNA, tubulin, histone deacetylases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Adriamycin's mechanism involves the formation of free radicals that damage DNA, leading to cell death. Cyclophosphamide's mechanism involves the formation of DNA cross-links that prevent DNA replication and transcription. Vindesine's mechanism involves the disruption of microtubule formation, which is essential for cell division. Valproic acid's mechanism involves the inhibition of histone deacetylases, which leads to the modulation of gene expression and the induction of apoptosis.
Approved indications
- Metastatic breast cancer, Metastatic ovarian cancer, Metastatic non-small cell lung cancer
- Multiple myeloma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Cardiotoxicity
- Neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: